Blurbs

Analysts’ Top Healthcare Picks: Aravive (ARAV), scPharmaceuticals (SCPH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aravive (ARAVResearch Report), scPharmaceuticals (SCPHResearch Report) and Applied DNA Sciences (APDNResearch Report) with bullish sentiments.

Aravive (ARAV)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aravive today and set a price target of $26.00. The company’s shares closed last Monday at $0.79, close to its 52-week low of $0.58.

According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -27.2% and a 19.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Bioline RX Ltd Sponsored ADR, and Lineage Cell Therapeutics.

Aravive has an analyst consensus of Moderate Buy, with a price target consensus of $26.00.

See Insiders’ Hot Stocks on TipRanks >>

scPharmaceuticals (SCPH)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on scPharmaceuticals today and set a price target of $15.00. The company’s shares closed last Monday at $4.02, close to its 52-week low of $3.48.

According to TipRanks.com, Tsao is a 3-star analyst with an average return of 1.9% and a 38.3% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Praxis Precision Medicines, and Crinetics Pharmaceuticals.

Currently, the analyst consensus on scPharmaceuticals is a Strong Buy with an average price target of $10.50, representing a 125.3% upside. In a report released today, SVB Securities also upgraded the stock to Buy with a $11.00 price target.

Applied DNA Sciences (APDN)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Applied DNA Sciences today and set a price target of $8.00. The company’s shares closed last Monday at $2.12.

According to TipRanks.com, Chen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -23.1% and a 26.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, EyePoint Pharmaceuticals, and Greenwich LifeSciences.

Currently, the analyst consensus on Applied DNA Sciences is a Moderate Buy with an average price target of $7.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ARAV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More